期刊文献+

替比夫定(素比伏)体外抑制乙型肝炎病毒复制的研究 被引量:1

Effect of telbivudine(sebivo)against HBV replication in vitro
下载PDF
导出
摘要 目的观察替比夫定体外对乙型肝炎病毒(HBV)复制的抑制作用。方法 HBV 复制子 pHBV1.3质粒转染 Huh7细胞,在转染细胞培养液中加入不同浓度的替比夫定,然后在不同时间段观察替比夫定的抗病毒作用。用 ELISA 检测培养上清中HBsAg、HBeAg 水平,用荧光定量 PCR(FQ-PCR)检测培养上清中 HBVDNA 拷贝数,用 Southern blot 分析转染细胞中 HBV 复制中间体。结果替比夫定减少了培养上清中 HBsAg、HBeAg 的表达及 HBV DNA 拷贝数,抑制了转染细胞中 HBV 复制中间体的形成。替比夫定对 HBV 复制子体外复制的抑制作用依赖于药物浓度及作用时间。结论替比夫定在体外对 HBV 有较强的抑制作用。 Objective To observe effect of telbivudine, a novel antiviral nucleoside analogue, against HBV replication in vitro. Methods After HBV replicon pHBV 1.3 plasmid was transfected into Huh7 cell line, telbivudine was administered to culture medium with different concentration, then antiviral effect of telbivudine was observed in different periods of time. The levels of HBsAg and HBeAg in supernatant of Huh7 cells were measured by ELISA and the number of HBV DNA by FQ-PCR. Intracellular HBV replicative intermediates were analyzed by Southern blot. Results Telbivudine reduced the levels of HBsAg and HBeAg and the numberofHBV DNA in supernatant of Huh7 cells, and also decreased intraeellular HBV replicative intermediates. The inhibition effect of telbivudine against HBV replication in vitro depended on drug concentration and action time. Conclusion Telbivudine greatly inhibits HBV replication in Huh7 cells transfected from pHBV1.3.
出处 《传染病信息》 2008年第4期235-237,共3页 Infectious Disease Information
关键词 乙型肝炎病毒 替比夫定 治疗 hepatitis Bvirns telbivudine therapy
  • 相关文献

参考文献3

二级参考文献28

  • 1Yin-ping LU,Bao-ju WANG,Ji-hua DONG,Zhao LIU,Shi-he GUAN,Meng-ji LU,Dong-liang YANG.Construction and Characterization of a Hepatitis B Virus Replicon[J].中国病毒学,2007,22(1):8-13. 被引量:5
  • 2Dlndri M, Volz T K, Lutgehetmann M, etal. 2005. Animal models for the study of HBV replication and its variants [J]. J Clin Viral, 34 (suppl 1):S54-62.
  • 3Guidotti L G, Matzke B, Schaller H, et al. 1995. High-level hepatitis B virus replication in transgenic mice[J]. J Virol, 69:6158-6169.
  • 4Guo Y, Guo H, Zhang L, et al. 2005. Genomic analysis of anti-hepatitis B virus (HBV) activity by small interfering RNA and lamivudine in stable HBV-producing cells [J]. J Virol, 79: 14392-14403.
  • 5Hadziyannis S J, Tassopoplos N C, Heathcote E J, et al.2003. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B [J]. N Engl J Meal,348:800-807.
  • 6Maddrey W C. 2000. Hepatitis B: an important public health issue[J]. J Med Virol, 61:362-366.
  • 7Mareellin P, Chang T T, Lim S G, et al. 2003. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B[J]. N Engl J Med, 348:808-816.
  • 8Park S G, Ryu H M, Lim S O, et ag. 2005. Interferon-gamma inhibits hepatitis B virus-induced NF-kappa B activation through nuclear localization of NF-kappa B-inducing kinase[J]. Gastroenterology, 128:2042-2053.
  • 9Sauerbrei A, Schacke M, Schultz U, etal. 2005. Alternative methods for validation of cell culture infection with duck hepatitis B virus [J]. J Virol Methods, 129:178-185.
  • 10Sells M A, Chen M L, Acs G. 1987. Production of hepatitis B virus particles in HepG2 ceils transfected with cloned hepatitis B virus[J]. Proc Natl Acad Sci USA, 84:1005-1009.

共引文献27

同被引文献25

  • 1Liaw YF, Gane E, Leung N, et al. 2-Year GLOBE trial results:telbivudine is superior to lamivudine in patients with chronic hepa-titis B[J]. Gastroenterology, 2009, 136(2):486-495.
  • 2Hou J, Yin YK, Xu D,et al. Telbivudine versus lamivudine in Chin-ese patients with chronic hepatitis B: results at 1 year of a randomized,double-blind trial[J]. Hepatology, 2008, 47(2):447-454.
  • 3Zheng MH, Shi KQ, Dai ZJ, et al. A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacyof telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients[J]. Clin Ther,2010, 32(4):649-658.
  • 4Boxer A, Protano MA, Vachon MC, et al. Telbivudine elevations ofCPK in chronic hepatitis B patients in a clinical setting[J]. J Hepatol,2010, 52(4 Suppl):533A.
  • 5Dang S, Gao N, Zhang X,et al. Rhabdomyolysis in a 48-year-oldman with hepatitis B-induced cirrhosis[J]. Am J Med Sci,2011, 342(1):73-75.
  • 6Finstere J, Ay L. Myotoxicity of telbivudine in pre-existing muscledamage[J]. Virol J, 2010, 7:323.
  • 7Fleischer RD, Lok AS. Myopathy and neuropathy associated withnucleos(t)ide analog therapy for hepatitis B[J]. J Hepatol, 2009, 51(4):787-791.
  • 8Marcellin P, Avila C,Wursthom K, et al. Telbivudine (LDT) pluspeg-interferon (PEGIFN) in HBeAg-positive chronic hepatitis B--very potent antiviral efficicy but risk of peripheral neuropathy (PN)[J]. J Hepatol, 2010, 52(Suppl 1):S6-S7.
  • 9Dalakas MC. Peripheral neuropathy and antiretroviral drugs[J]. JPeripher Nerv Syst, 2001, 6(1):14-20.
  • 10Brinkman K, ter Hofstede HJ, Burger DM, et al. Adverse effects ofreverse transcriptase inhibitors: mitochondrial toxicity as common.pathway[J]. AIDS, 1998, 12(14):1735-1744.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部